Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      Department of Urology, University Hospital RWTH Aachen University, Aachen, Germany
      Institute of Pathology, University Hospital RWTH Aachen University, Aachen, Germany
      Department of Urology, HELIOS Hospital, Bad Saarow, Germany
      Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
      Institute of Pathology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
      Department of Urology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    • Corporate Authors:
    • Abstract:
      Background: Immune checkpoint inhibitors (ICI) are an integral part of bladder cancer therapy, however, the relevance of ICI treatment for mixed and pure squamous cell carcinoma of the bladder remains poorly studied. Therefore, we analysed the expression of programmed death-ligand 1 (PD-L1) in urothelial carcinomas with squamous differentiation (UC/SCC) and pure squamous cell carcinoma (SCC) of the bladder and studied a UC/SCC patient with ICI therapy.Methods: Tissue microarrays of 45 UC/SCC and 63 SCC samples were immunohistochemically stained with four anti-PD-L1 antibodies (28-8, 22C3, SP142 and SP263). PD-L1 expression was determined for tumour cells (TP-Score), immune cells (IC-Score) and combined (CPS, combined positive score). In addition, we present clinical and histological data of an UC/SCC patient with nivolumab therapy.Results: Overall, positive PD-L1 staining ranged between 4.8 and 61.9% for IC and 0 and 51.2% for TC depending on the used antibody. There were no significant differences between UC/SCC and SCC. According to current FDA guidelines for example for first line therapy of urothelial cancer with pembrolizumab (CPS ≥ 10), a subset of SCC patients up to 20% would be eligible. Finally, our UC/SCC index patient revealed excellent therapy response regarding his lung metastasis.Conclusions: Our data reveal a PD-L1 expression in squamous differentiated carcinomas comparable with current data shown for urothelial tumours. In accordance with the encouraging clinical data of the index patient we suggest ICI treatment also for mixed and pure SCC of the urinary bladder.
    • Journal Subset:
      Biomedical; Europe; UK & Ireland
    • ISSN:
      1471-2407
    • MEDLINE Info:
      PMID: NLM32188412 NLM UID: 100967800
    • Publication Date:
      In Process
    • Publication Date:
      20200326
    • DOI:
      10.1186/s12885-020-06727-2
    • Accession Number:
      142314174
  • Citations
    • ABNT:
      MORSCH, R. et al. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. BMC Cancer, [s. l.], v. 20, n. 1, p. 1–10, 2020. DOI 10.1186/s12885-020-06727-2. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=142314174. Acesso em: 25 set. 2020.
    • AMA:
      Morsch R, Rose M, Maurer A, et al. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. BMC Cancer. 2020;20(1):1-10. doi:10.1186/s12885-020-06727-2
    • APA:
      Morsch, R., Rose, M., Maurer, A., Cassataro, M. A., Braunschweig, T., Knüchel, R., Vögeli, T.-A., Ecke, T., Eckstein, M., Weyerer, V., Esposito, I., Ackermann, M., Niegisch, G., Gaisa, N. T., & on behalf of the German Study Group of Bladder Cancer (DFBK e.V.). (2020). Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. BMC Cancer, 20(1), 1–10. https://doi.org/10.1186/s12885-020-06727-2
    • Chicago/Turabian: Author-Date:
      Morsch, Ronja, Michael Rose, Angela Maurer, Maria Angela Cassataro, Till Braunschweig, Ruth Knüchel, Thomas-Alexander Vögeli, et al. 2020. “Therapeutic Implications of PD-L1 Expression in Bladder Cancer with Squamous Differentiation.” BMC Cancer 20 (1): 1–10. doi:10.1186/s12885-020-06727-2.
    • Harvard:
      Morsch, R. et al. (2020) ‘Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation’, BMC Cancer, 20(1), pp. 1–10. doi: 10.1186/s12885-020-06727-2.
    • Harvard: Australian:
      Morsch, R, Rose, M, Maurer, A, Cassataro, MA, Braunschweig, T, Knüchel, R, Vögeli, T-A, Ecke, T, Eckstein, M, Weyerer, V, Esposito, I, Ackermann, M, Niegisch, G, Gaisa, NT & on behalf of the German Study Group of Bladder Cancer (DFBK e.V.) 2020, ‘Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation’, BMC Cancer, vol. 20, no. 1, pp. 1–10, viewed 25 September 2020, .
    • MLA:
      Morsch, Ronja, et al. “Therapeutic Implications of PD-L1 Expression in Bladder Cancer with Squamous Differentiation.” BMC Cancer, vol. 20, no. 1, Mar. 2020, pp. 1–10. EBSCOhost, doi:10.1186/s12885-020-06727-2.
    • Chicago/Turabian: Humanities:
      Morsch, Ronja, Michael Rose, Angela Maurer, Maria Angela Cassataro, Till Braunschweig, Ruth Knüchel, Thomas-Alexander Vögeli, et al. “Therapeutic Implications of PD-L1 Expression in Bladder Cancer with Squamous Differentiation.” BMC Cancer 20, no. 1 (March 18, 2020): 1–10. doi:10.1186/s12885-020-06727-2.
    • Vancouver/ICMJE:
      Morsch R, Rose M, Maurer A, Cassataro MA, Braunschweig T, Knüchel R, et al. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. BMC Cancer [Internet]. 2020 Mar 18 [cited 2020 Sep 25];20(1):1–10. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=142314174